VNDA (Vanda) צמיחת רווח נקי למניה השנה

Cost optimization through the outsourcing of production and logistics serves as a key driver for Vanda Pharmaceuticals (VNDA). The annual change in EPS visualizes this effect, where 32.20 shows the current value of the metric. Stability is supported by the brand's high authority in neuropsychiatry and a mature portfolio of insomnia treatments protected by strict patent rights.

For Vanda Pharmaceuticals (VNDA), which specializes in drugs for the therapy of psychiatric disorders, this indicator serves as a measure of the effectiveness of monetizing patented developments. By analyzing the earnings per share growth compared to the previous year on the GURU.Markets platform, an investor assesses the annual dynamics of net income per share, which allows for the timely diagnosis of business stagnation and prevents overpaying for an asset with fading potential.